Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DEA Takes Comments On Kratom, But Keeps Eye On Scheduling

This article is powered by The Rose Sheet

Executive Summary

DEA will accept comments through Dec. 1 on its proposal to move the active materials in kratom into Schedule I under CSA to avoid an imminent hazard to public safety.


Related Content

Kratom Group Sharpens Criticism Of 'Opioid' Finding In FDA's Report To DEA
Opioid Withdrawal Treatment Claims Spur FDA's Latest Kratom Warnings
AHPA Backs NDI Filing For Kratom, Experts Question FDA Enforcement
Kratom Experts Seek NIDA As Ally To Show Herb's Safety And Benefits
After 10 Years, Congressional Supplement Caucus Sustains Momentum
DEA Proposal To Schedule Kratom Stirs Wave Of Opposition
More Time For NDI Guidance Comment: Health And Wellness Industry News Roundup
Kratom Reprieve From Scheduling Requested By House Members
Kratom In Supplements Reaches Dead End On DEA Direct Regulatory Path





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts